This article has been updated with additional information about Myriad's stock performance and analysts' notes. 

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal fourth quarter revenues dipped 2 percent year over year.

Myriad's surprising results and forecast sent its shares tumbling to a 52-week low.

For the three months ended June 30, total revenues were $186.5 million, compared to $189.9 million in the year-ago period and below analysts' expectation of $187.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.